SG11201406207PA - Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof - Google Patents
Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereofInfo
- Publication number
- SG11201406207PA SG11201406207PA SG11201406207PA SG11201406207PA SG11201406207PA SG 11201406207P A SG11201406207P A SG 11201406207PA SG 11201406207P A SG11201406207P A SG 11201406207PA SG 11201406207P A SG11201406207P A SG 11201406207PA SG 11201406207P A SG11201406207P A SG 11201406207PA
- Authority
- SG
- Singapore
- Prior art keywords
- mnk2
- mnk1
- modulators
- bicyclic heterocyclic
- heterocyclic derivatives
- Prior art date
Links
- 101100184273 Caenorhabditis elegans mnk-1 gene Proteins 0.000 title 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1205669.3A GB201205669D0 (en) | 2012-03-30 | 2012-03-30 | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
PCT/SG2013/000126 WO2013147711A1 (en) | 2012-03-30 | 2013-04-01 | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201406207PA true SG11201406207PA (en) | 2014-11-27 |
Family
ID=46160013
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406207PA SG11201406207PA (en) | 2012-03-30 | 2013-04-01 | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof |
SG10201706594PA SG10201706594PA (en) | 2012-03-30 | 2013-04-01 | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201706594PA SG10201706594PA (en) | 2012-03-30 | 2013-04-01 | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (3) | US9908886B2 (ja) |
EP (2) | EP3321268A1 (ja) |
JP (2) | JP6475158B2 (ja) |
KR (1) | KR102153320B1 (ja) |
CN (1) | CN104350055B (ja) |
AU (2) | AU2013240612B2 (ja) |
BR (1) | BR112014024255B1 (ja) |
DK (1) | DK2831079T3 (ja) |
ES (1) | ES2647959T3 (ja) |
GB (1) | GB201205669D0 (ja) |
NO (1) | NO2831079T3 (ja) |
PL (1) | PL2831079T3 (ja) |
SG (2) | SG11201406207PA (ja) |
WO (1) | WO2013147711A1 (ja) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013234955A1 (en) | 2012-03-23 | 2014-11-13 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途 |
CA2898294C (en) | 2013-02-21 | 2020-06-09 | Calitor Sciences, Llc | Heteroaromatic compounds as pi3 kinase modulators |
US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
TW201542550A (zh) | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
GB2518873A (en) * | 2013-10-03 | 2015-04-08 | Agency Science Tech & Res | Bicyclic alkyne derivatives and uses thereof |
JP6469692B2 (ja) * | 2013-12-09 | 2019-02-13 | ユーシービー バイオファルマ エスピーアールエル | Tnf活性のモジュレーターとしてのイミダゾピリジン誘導体 |
LT3083627T (lt) | 2013-12-19 | 2018-12-27 | Novartis Ag | [1,2,4]triazolo[1,5-a]pirimidino dariniai kaip protozoano proteasomos inhibitoriai, skirti parazitinių ligų tokių kaip leišmaniozė, gydymui |
ES2728932T3 (es) * | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
UA121206C2 (uk) | 2014-01-24 | 2020-04-27 | Турнінґ Поінт Терапьютикс, Інк. | Діарильні макроцикли як модулятори протеїнкіназ |
EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ES2901711T3 (es) | 2014-02-13 | 2022-03-23 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
DK3285809T3 (da) | 2015-04-20 | 2019-11-18 | Effector Therapeutics Inc | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. |
SG11201708190UA (en) * | 2015-04-29 | 2017-11-29 | Janssen Pharmaceutica Nv | Azabenzimidazoles and their use as ampa receptor modulators |
US10919875B2 (en) | 2015-06-18 | 2021-02-16 | 89Bio Ltd | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
US9902696B2 (en) | 2015-06-18 | 2018-02-27 | Cephalon, Inc. | 1,4-substituted piperidine derivatives |
CN107735399B (zh) | 2015-07-02 | 2021-01-26 | 特普医药公司 | 作为蛋白质激酶的调节剂的手性二芳基大环 |
CN113354653A (zh) | 2015-07-06 | 2021-09-07 | 特普医药公司 | 二芳基大环多晶型物及其制备方法 |
KR20180033194A (ko) | 2015-07-21 | 2018-04-02 | 티피 테라퓨틱스, 인크. | 키랄 디아릴 매크로사이클 및 이것의 용도 |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
JP2018526452A (ja) | 2015-09-03 | 2018-09-13 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Dyrk1aの小分子抑制剤およびその使用 |
KR20180073629A (ko) * | 2015-10-22 | 2018-07-02 | 셀비타 에스에이 | 피리돈 유도체 및 키나제 억제제로서의 그의 용도 |
US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
JP6888006B2 (ja) | 2015-10-29 | 2021-06-16 | イーフェクター セラピューティクス, インコーポレイテッド | Mnk1およびmnk2を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物 |
EA201891049A1 (ru) | 2015-10-29 | 2018-10-31 | Эффектор Терапьютикс, Инк. | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 |
WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
US20170191136A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
KR20190034225A (ko) | 2016-07-28 | 2019-04-01 | 티피 테라퓨틱스, 인크. | 거대환 키나제 억제제 |
GB201700692D0 (en) * | 2017-01-16 | 2017-03-01 | Salvensis | Novel compounds and their use in the treatment of schistosomiasis |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
MX2019009653A (es) | 2017-02-14 | 2019-12-19 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos. |
MY201925A (en) | 2017-07-28 | 2024-03-23 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
HRP20221502T1 (hr) | 2017-12-19 | 2023-03-31 | Turning Point Therapeutics, Inc. | Makrociklički spojevi za liječenje bolesti |
CN110156786B (zh) * | 2018-02-13 | 2022-06-03 | 青煜医药研发(上海)有限公司 | 嘧啶并环化合物及其制备方法和应用 |
JP7335882B2 (ja) * | 2018-02-13 | 2023-08-30 | ブルーレイ セラピューティクス (シャンハイ) カンパニー,リミティド | ピリミジン縮合環式化合物及びその製造方法、並びに使用 |
EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
US12054483B2 (en) | 2018-09-28 | 2024-08-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | CRYSTALLINE FORMS OF MNK INHIBITORS |
CN111978317A (zh) * | 2019-05-22 | 2020-11-24 | 上海道熵生物科技有限公司 | 咪唑并吡啶类mnk1/mnk2激酶抑制剂及其制备方法和应用 |
CN111978325B (zh) * | 2019-05-22 | 2023-11-17 | 中国药科大学 | 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用 |
US20220396575A1 (en) * | 2019-08-30 | 2022-12-15 | Tsd Life Sciences Co., Ltd. | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
US20230093480A1 (en) * | 2019-12-30 | 2023-03-23 | Devicare SL | Compositions for clinical complications associated to devices implanted in the urinary tract |
US20230355617A1 (en) * | 2020-09-14 | 2023-11-09 | The University Of Sussex | Small molecule inhibitors of lemur tyrosine kinase 3 |
CN112047950B (zh) * | 2020-09-14 | 2023-07-25 | 华东师范大学 | 咪唑并吡嗪类衍生物及其合成方法和应用 |
US20230000986A1 (en) * | 2021-07-01 | 2023-01-05 | Board Of Regents, The University Of Texas System | Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged |
CN117203211A (zh) * | 2021-11-29 | 2023-12-08 | 中国海洋大学 | 咪唑并噻唑衍生物及其制备方法与应用 |
CN114113639B (zh) * | 2022-01-29 | 2022-04-19 | 北京大有天弘科技有限公司 | 一种血型抗体检测方法及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
EP1991547A2 (en) | 2006-03-09 | 2008-11-19 | Pharmacopeia, Inc. | 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders |
BRPI0713328A2 (pt) | 2006-06-22 | 2012-10-30 | Biovitrum Ab | derivados de piridina e pirazina como inibidores de cinase mnk |
WO2008058126A2 (en) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
US20120058997A1 (en) * | 2006-11-06 | 2012-03-08 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
JP5442448B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | Fgfrインヒビターとしての二環式ヘテロ環式化合物 |
AR067326A1 (es) * | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
ES2393430T3 (es) * | 2007-10-17 | 2012-12-21 | Novartis Ag | Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK |
US20110280886A1 (en) * | 2008-11-12 | 2011-11-17 | University Hospital Basel | Treating cancer by modulating mnk |
TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
IN2012DN01961A (ja) * | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
TW201144310A (en) * | 2010-04-28 | 2011-12-16 | Daiichi Sankyo Co Ltd | [5,6] heterocyclic compound |
CN103384670B (zh) * | 2010-07-28 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的咪唑并[1,2-b]哒嗪 |
US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
CA2901427A1 (en) * | 2013-03-07 | 2014-09-12 | Califia Bio, Inc. | Mixed lineage kinase inhibitors and method of treatments |
-
2012
- 2012-03-30 GB GBGB1205669.3A patent/GB201205669D0/en not_active Ceased
-
2013
- 2013-04-01 JP JP2015503165A patent/JP6475158B2/ja active Active
- 2013-04-01 US US14/363,718 patent/US9908886B2/en active Active
- 2013-04-01 KR KR1020147027686A patent/KR102153320B1/ko active IP Right Grant
- 2013-04-01 BR BR112014024255-0A patent/BR112014024255B1/pt active IP Right Grant
- 2013-04-01 SG SG11201406207PA patent/SG11201406207PA/en unknown
- 2013-04-01 WO PCT/SG2013/000126 patent/WO2013147711A1/en active Application Filing
- 2013-04-01 NO NO13768800A patent/NO2831079T3/no unknown
- 2013-04-01 CN CN201380027654.7A patent/CN104350055B/zh active Active
- 2013-04-01 DK DK13768800.8T patent/DK2831079T3/da active
- 2013-04-01 ES ES13768800.8T patent/ES2647959T3/es active Active
- 2013-04-01 SG SG10201706594PA patent/SG10201706594PA/en unknown
- 2013-04-01 EP EP17179630.3A patent/EP3321268A1/en active Pending
- 2013-04-01 PL PL13768800T patent/PL2831079T3/pl unknown
- 2013-04-01 EP EP13768800.8A patent/EP2831079B1/en active Active
- 2013-04-01 AU AU2013240612A patent/AU2013240612B2/en active Active
-
2017
- 2017-08-24 AU AU2017219039A patent/AU2017219039A1/en not_active Abandoned
-
2018
- 2018-01-16 US US15/872,571 patent/US20180208600A1/en not_active Abandoned
- 2018-10-31 JP JP2018206109A patent/JP6662984B2/ja active Active
-
2019
- 2019-06-05 US US16/432,469 patent/US11040978B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN104350055B (zh) | 2019-05-31 |
JP2019031560A (ja) | 2019-02-28 |
SG10201706594PA (en) | 2017-09-28 |
US9908886B2 (en) | 2018-03-06 |
EP2831079A4 (en) | 2015-11-18 |
JP6662984B2 (ja) | 2020-03-11 |
DK2831079T3 (da) | 2017-11-27 |
US20190315755A1 (en) | 2019-10-17 |
AU2013240612A1 (en) | 2014-10-16 |
GB201205669D0 (en) | 2012-05-16 |
WO2013147711A1 (en) | 2013-10-03 |
US11040978B2 (en) | 2021-06-22 |
US20140371199A1 (en) | 2014-12-18 |
KR20150002639A (ko) | 2015-01-07 |
JP2015511638A (ja) | 2015-04-20 |
EP2831079B1 (en) | 2017-08-16 |
EP3321268A1 (en) | 2018-05-16 |
AU2013240612B2 (en) | 2017-05-25 |
CN104350055A (zh) | 2015-02-11 |
ES2647959T3 (es) | 2017-12-27 |
US20180208600A1 (en) | 2018-07-26 |
JP6475158B2 (ja) | 2019-02-27 |
EP2831079A1 (en) | 2015-02-04 |
BR112014024255B1 (pt) | 2021-12-28 |
BR112014024255A2 (pt) | 2017-06-20 |
PL2831079T3 (pl) | 2018-01-31 |
AU2017219039A1 (en) | 2017-09-14 |
NO2831079T3 (ja) | 2018-01-13 |
KR102153320B1 (ko) | 2020-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201706594PA (en) | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof | |
HRP20181310T1 (hr) | Novi heterociklički derivati i njihova uporaba | |
HK1207069A1 (en) | Heterocyclic compounds and uses thereof | |
EP2828258A4 (en) | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE | |
HK1201521A1 (en) | Heterocyclic compounds and methods for their use | |
SG11201503535PA (en) | Hollow hydrogel capsules and methods of using the same | |
HK1201531A1 (en) | Heterocyclic compounds and methods for their use | |
HK1201533A1 (en) | Heterocyclic compounds and methods for their use | |
AP3611A (en) | Heterocyclic compounds and their uses | |
HK1198833A1 (en) | N-acylpeptide derivatives and their uses n- | |
HK1198949A1 (en) | Absorber and absorbent article using the same | |
EP2909181A4 (en) | PKM2 MODULATORS AND METHODS OF USING SAME | |
IL252033B (en) | History of spiro and processes for their preparation | |
HK1204327A1 (en) | Aurora and flt3 kinases modulators flt3 | |
GB2500340B (en) | Carrying aid especially for use with children | |
EP2870133A4 (en) | TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF | |
GB201212570D0 (en) | Carrying aid especially for use with children |